February 16, 2021
Targeted Protein Degradation in Oncology and Beyond
2nd Annual North American Protein Degradation Congress
Read More
December 7, 2020
KTX-120, A Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL Cell and Patient Derived Xenograft Models
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
MYD88 Tumors
Read More
December 7, 2020
Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
MYD88 Tumors
Read More
December 7, 2020
Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Liquid Tumors
Read More
November 3, 2020
IRAK4 Degrader to Take on Innate Immunity
Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020)
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 15, 2020
Targeted Protein Degradation Beyond Oncology
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi
Read More
October 14, 2020
PK/PD Relationship in Targeted Protein Degradation
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Rong
Read More
October 9, 2020
Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa
5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Hidradenitis Suppurativa (HS)
Read More
June 22, 2020
A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Liquid Tumors
Solid Tumors
Read More
June 22, 2020
IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo
American Association for Cancer Research (AACR) Virtual Annual Meeting II
MYD88 Tumors
Read More